241 related articles for article (PubMed ID: 15133630)
1. Functional characterization of T lymphocytes derived from patients with acute myelogenous leukemia and chemotherapy-induced leukopenia.
Wendelbo Ø; Nesthus I; Sjo M; Paulsen K; Ernst P; Bruserud Ø
Cancer Immunol Immunother; 2004 Aug; 53(8):740-7. PubMed ID: 15133630
[TBL] [Abstract][Full Text] [Related]
2. The effect of short-course high-dose corticosteroid therapy on peripheral blood CD34+ progenitor cells in children with acute leukemia.
Cetin M; Hiçsönmez G; Tuncer AM; Kansu E; Canpynar H
Exp Hematol; 1996 Aug; 24(10):1191-4. PubMed ID: 8765493
[TBL] [Abstract][Full Text] [Related]
3. T-lymphocyte functions in acute leukaemia patients with severe chemotherapy-induced cytopenia: characterization of clonogenic T-cell proliferation.
Bruserud O; Ulvestad E; Berentsen S; Bergheim J; Nesthus I
Scand J Immunol; 1998 Jan; 47(1):54-62. PubMed ID: 9467659
[TBL] [Abstract][Full Text] [Related]
4. The cellular immune system of patients with acute leukemia and severe chemotherapy-induced leukopenia: characterization of T lymphocyte subsets responsive to IL-16 and IL-17.
Bruserud O; von Volkman HL; Ulvestad E
Acta Haematol; 2000; 104(2-3):80-91. PubMed ID: 11154979
[TBL] [Abstract][Full Text] [Related]
5. Acute myelogenous leukemia with T-cell features.
Ribrag V; Bayle C; Brault P; Bodis S; Magherini E; Hayat M
Bull Cancer; 1992; 79(12):1165-71. PubMed ID: 1304836
[TBL] [Abstract][Full Text] [Related]
6. Intensive chemotherapy for acute myeloid leukemia differentially affects circulating TC1, TH1, TH17 and TREG cells.
Ersvaer E; Liseth K; Skavland J; Gjertsen BT; Bruserud Ø
BMC Immunol; 2010 Jul; 11():38. PubMed ID: 20618967
[TBL] [Abstract][Full Text] [Related]
7. Effect of phytohemagglutinin and interleukin-2 on malignant and nonmalignant B and T lymphocytes.
Porwit A; Panayotides P; Wasserman J; Reizenstein P
Cancer Detect Prev; 1988; 12(1-6):91-6. PubMed ID: 3263204
[TBL] [Abstract][Full Text] [Related]
8. Effects of imipenem and cilastatin on human T-lymphocytes derived from acute leukemia patients with chemotherapy-induced leucopenia: studies of T-lymphocyte responses in the presence of acute myelogenous leukemia (AML) blast accessory cells.
Bruserud O
Int J Immunopharmacol; 2000 Jan; 22(1):69-81. PubMed ID: 10684990
[TBL] [Abstract][Full Text] [Related]
9. Cytokine responsiveness of mitogen-activated T cells derived from acute leukemia patients with chemotherapy-induced leukopenia.
Bruserud O; Ulvestad E
J Interferon Cytokine Res; 2000 Nov; 20(11):947-54. PubMed ID: 11096451
[TBL] [Abstract][Full Text] [Related]
10. Classification of acute non-lymphocytic leukemia according to the distribution picture of peroxidase activity and cell size: correlation between the classification and therapeutic response.
Takubo T; Kubota Y; Oguma S; Ueda T; Shibata H; Nakamura H; Masaoka T; Yoshitake J; Ishigami S
Blood Cells; 1983; 9(3):501-14. PubMed ID: 6586210
[TBL] [Abstract][Full Text] [Related]
11. Cellular immune responses in acute leukaemia patients with severe chemotherapy-induced leucopenia; characterization of the cytokine repertoire of clonogenic T cells.
Bruserud O
Cancer Immunol Immunother; 1998 Jun; 46(4):221-8. PubMed ID: 9671145
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-7 (IL-7) in patients receiving intensive chemotherapy for acute myelogenous leukemia: studies of systemic IL-7 Levels and IL-7 responsiveness of circulating T lymphocytes.
Wendelbo Ø; Glenjen N; Bruserud Ø
J Interferon Cytokine Res; 2002 Oct; 22(10):1057-65. PubMed ID: 12433286
[TBL] [Abstract][Full Text] [Related]
13. T-cell qualities of lymphocytes and/or leukemic cells from peripheral blood in acute myeloid and lymphatic leukemia before treatment and at relapse.
de Vaan GA; Bakkeren JA; Schretlen ED
Biomedicine; 1975 Nov; 22(6):524-31. PubMed ID: 1083749
[TBL] [Abstract][Full Text] [Related]
14. [Effect of interleukin 2 on blast proliferative activity and expression of T-cell markers in patients with acute lymphoblastic leukemia].
Tsveĭbakh AS; Kazhdan IIa; Filatov AV; Kariagin IE; Afanas'ev BV
Ter Arkh; 1988; 60(5):24-9. PubMed ID: 3051486
[TBL] [Abstract][Full Text] [Related]
15. Plasma ammonia in patients with acute leukemia.
Xu SR; Yao EG; Dong ZR; Liu RS; Pan L; Lin FR; Zhang RX; Liu MC; Ma BB; Yin JQ
Chin Med J (Engl); 1992 Sep; 105(9):713-6. PubMed ID: 1288971
[TBL] [Abstract][Full Text] [Related]
16. Human acute myelogenous leukemia antigens defined by simian antisera: evidence for leukemia-associated antigens distinct from immune response-associated alloantigens.
Mohanakumar T; Russell EC; Metzgar RS; Dunn N; Phibbs M; McWilliams NB; Maurer HM
J Natl Cancer Inst; 1979 May; 62(5):1163-7. PubMed ID: 86633
[TBL] [Abstract][Full Text] [Related]
17. Numbers and cytotoxicities of CD3+CD56+ T lymphocytes in peripheral blood of patients with acute myeloid leukemia and acute lymphocytic leukemia.
Guo W; Xing C; Dong A; Lin X; Lin Y; Zhu B; He M; Yao R
Cancer Biol Ther; 2013 Oct; 14(10):916-21. PubMed ID: 24030391
[TBL] [Abstract][Full Text] [Related]
18. Antibody-dependent monocyte-mediated cytotoxicity. Serial studies in acute myeloid leukaemia.
Kragballe K; Ellegaard J
Scand J Haematol; 1980 Aug; 25(2):181-90. PubMed ID: 6936773
[TBL] [Abstract][Full Text] [Related]
19. Suppression of lymphoproliferative responses to alloantigens by autologous AML cells.
Taylor GM; Fergusson WD; Harris R
Clin Exp Immunol; 1979 Jan; 35(1):53-61. PubMed ID: 154982
[TBL] [Abstract][Full Text] [Related]
20. Soluble Fas/Apo-1 (CD95) levels during T cell activation in the presence of acute myelogenous leukemia accessory cells; contributions from local release and variations in systemic levels.
Bruserud O; Ulvestad E
Cancer Immunol Immunother; 2000 Sep; 49(7):377-87. PubMed ID: 10999464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
